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Abstract
Substantial harm could result from concurrent cigarette and e-cigarette use (i.e., dual use) were it 
to undermine smoking cessation. Perceptions of chemical exposure and resulting harms may 
influence dual use. We conducted a probability-based phone survey of 1164 U.S. adult cigarette 
smokers in 2014–2015 and analyzed results in 2016. In a between-subjects experiment, smokers 
heard a hypothetical scenario in which cigarettes and e-cigarettes had the same amount of harmful 
chemicals or cigarettes had more chemicals than e-cigarettes (10× more, 100× more, or chemicals 
were present only in cigarettes). Smokers indicated how the scenario would change their interest in 
dual use and perceived health harms. Few smokers (7%) who heard that the products have the 
same amount of chemicals were interested in initiating or increasing dual use. However, more 
smokers were interested when told that cigarettes have 10× more chemicals than e-cigarettes 
(31%), 100× more chemicals than e-cigarettes (32%), or chemicals were present only in cigarettes 
(43%) (all p < .001). Individuals told that cigarettes have more chemicals were more likely than 
those in the “same amount” scenario to perceive that cigarettes would be more harmful than e-
cigarettes (79% vs. 41%, OR = 5.41, 95% CI = 4.08–7.17). These harm perceptions partially 
explained the relationship between chemical scenario and dual use interest. Smokers associated 
higher chemical amounts in cigarettes versus e-cigarettes with greater health harms from cigarettes 
and thus expressed increased interest in dual use. The findings suggest that disclosing amounts of 
chemicals in cigarette smoke and e-cigarette aerosol could unintentionally encourage dual use.
Keywords
Smoking; Electronic cigarettes; Tobacco products
*Corresponding author at: RTI International, 3040 E. Cornwallis Road, Research Triangle Park, NC 27709-2194, USA. 
jpepper@rti.org (J.K. Pepper). 
HHS Public Access
Author manuscript
Prev Med. Author manuscript; available in PMC 2018 March 01.
Published in final edited form as:
Prev Med. 2017 March ; 96: 144–148. doi:10.1016/j.ypmed.2016.12.025.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
1. Introduction
The toxic constituents (chemicals) in cigarette smoke, including at least 71 carcinogens, 
directly contribute to the burden of disease caused by cigarette smoking (Talhout et al., 
2011). The 2009 Family Smoking Prevention and Tobacco Control Act requires tobacco 
companies to report to the U.S. Food and Drug Administration (FDA) the quantity of each 
harmful or potentially harmful smoke constituent for each brand and sub-brand of cigarettes 
(11th Congress of the United States of America, 2009). FDA must then disclose this 
information to the public in a way that is “understandable” and not “misleading to a lay 
person” (U.S. Food and Drug Administration, 2011). U.S. adults have little knowledge of 
most of the chemicals in cigarette smoke (Hall et al., 2014), and when presented with 
general information about chemicals and their quantities, most adults have difficulty 
interpreting this information (Neil et al., 1994). One consideration for FDA in determining 
how to disclose constituent information in cigarettes may be the impact of this information 
on use of e-cigarettes, another product that FDA now regulates and will eventually require 
manufacturers to report the levels of constituents (U.S. Food and Drug Administration, 
2016).
One public health concern about disclosing cigarette smoke constituent information to the 
public is that smokers may respond by initiating or increasing e-cigarette use without 
quitting cigarette smoking (i.e., engaging in dual use of these products). Although quitting 
smoking dramatically improves health outcomes, reductions in the amount of cigarette 
smoking appear to have few or minor benefits unless the reductions are both substantial 
(down to <50% of baseline use) and sustained over time (Begh et al., 2015; Pisinger and 
Godtfredsen, 2007). Thus, starting or increasing e-cigarette use, even if accompanied by 
some reduction in cigarette smoking, is unlikely to lead to improved health outcomes. E-
cigarette advertising claims (e.g., that e-cigarettes produce only “harmless water vapor” or 
contain “no carcinogens”) (Grana and Ling, 2014) and positive interpersonal communication 
from e-cigarette enthusiasts (Pepper et al., 2014) may be encouraging dual use of e-
cigarettes and traditional cigarettes. Dual use is potentially problematic because it could 
maintain smokers’ nicotine addiction, making it more difficult to quit using tobacco 
(Schroeder and Hoffman, 2014). Smokers trying to use e-cigarettes to quit smoking often 
use a tapering approach to reduce their cigarette smoking over time (Pepper and Brewer, 
2014; Rutten et al., 2015), which for some individuals may be a less successful strategy than 
“quitting cold turkey” for achieving successful cessation (Cheong et al., 2007). Furthermore, 
e-cigarette use exposes users to aerosolized e-liquid, a mix of unregulated and often 
unknown chemical ingredients, some of which have been found to be toxic (Barrington-
Trimis et al., 2014; Goniewicz et al., 2014).
Understanding smokers’ harm perceptions about chemicals in traditional cigarettes and e-
cigarettes is important for two reasons. First, it could provide insight into smokers’ decisions 
about dual use. Second, it has regulatory implications. The FDA is currently considering 
how best to publicly display information on the amounts of harmful chemicals in traditional 
cigarettes and e-cigarettes and whether certain tobacco products like e-cigarettes could be 
approved as “modified risk tobacco products” on the basis of their amounts of harmful 
constituents (U.S. Food and Drug Administration, 2015). Thus, the goal of our study was to 
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explore the impact of hypothetical scenarios describing the amounts of chemicals in e-
cigarettes relative to cigarettes on smokers’ interest in initiating or increasing dual use. We 
further explored the relationship between scenarios and interest in dual use with anticipated 
perceptions about the health harms caused by cigarettes versus e-cigarettes.
2. Methods
2.1. Sample
From September 2014 to May 2015, we recruited a probability sample of 5014 U.S. adults, 
including 1164 smokers (Boynton et al., 2016; Brewer et al., 2016). Our paper focuses on an 
experiment conducted with established cigarette smokers (defined as those who reported 
smoking “some days” or “every day” and who had smoked at least 100 cigarettes in their 
lifetime). We identified participants through random-digit-dial landline and cell phone 
sampling frames with 98% coverage of the U.S. population. We oversampled cell phone 
numbers and geographic areas with higher rates of poverty and smoking. To be eligible for 
study participation, adults had to be aged 18 or older and speak English or Spanish. Boynton 
and colleagues have provided additional details on sampling design, survey methods, and 
sample characteristics (Boynton et al., 2016). The response rate among adults was 42%, 
calculated using AAPOR formula 4 (American Association for Public Opinion Research, 
2016; Boynton et al., 2016). The University of North Carolina’s institutional review board 
approved the study.
2.2. Procedure and measures
Interviewers obtained verbal consent before starting the interview. Participants heard a broad 
description of e-cigarettes at the beginning of the interview (“The next few questions are 
about electronic or e-cigarettes and other vaping devices, such as e-hookah and vape pens. 
Popular brands include Blu, Vuse, NJOY, and Flavor Vapes.”). Later in the interview, before 
responding to the experimental items, interviewers told participants, “In the next questions, 
I’ll say ‘e-cigarettes’ to also refer to other vaping devices.” Survey software randomized 
cigarette smokers to 1 of 4 scenarios describing hypothetical amounts of chemicals in 
cigarettes and e-cigarettes: “What if… [the amount of harmful chemicals in cigarettes was 
the same as in e-cigarettes; the amount of harmful chemicals in cigarettes was about 10 
times higher than in e-cigarettes; the amount of harmful chemicals in cigarettes was about 
100 times higher than in e-cigarettes; cigarettes had harmful chemicals, but e-cigarettes did 
not].” We hereafter refer to these scenarios as “same amount,” “10 times more” [in cigarettes 
compared with e-cigarettes], “100 times more” [in cigarettes compared with e-cigarettes], 
and “chemicals present” [in cigarettes versus absent in e-cigarettes].
Next, smokers were asked how this scenario would affect their perceptions of harm: “Would 
this make you think that cigarettes cause more health problems than e-cigarettes?” (“no” 
coded as 0 and “yes” as 1). For parsimony, we refer to these anticipated perceptions, which 
represent their imagined response to the scenario, as “harm perceptions” or “perceived 
harm.” Interviewers then asked smokers who were not current e-cigarette users whether 
learning the information in the scenario would make them start using e-cigarettes. If smokers 
were already current e-cigarette users, interviewers asked if the information in the scenario 
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would make them use e-cigarettes less, the same amount, or more. Finally, respondents were 
asked whether the chemical information described in the scenario would make them stop 
smoking traditional tobacco cigarettes, smoke less, smoke the same amount, or smoke more. 
We recoded participants’ answers to these items such that a value of “1” corresponded to 
interest in initiating or increasing dual use of the products. We defined this type of interest as 
the participant stating that she or he would decrease, continue, or increase cigarette smoking 
(i.e., any smoking behavior other than quitting) while also starting or increasing e-cigarette 
use. We coded all other combinations of behaviors as “0.”
Demographic measures included sex, age, race, Hispanic/Latino ethnicity, educational 
attainment (high school or less; some college or associate’s degree; bachelor’s degree or 
more), and geographic region. We coded participants as having low socioeconomic status if 
they had a household income below the federal poverty level, they had less than a high 
school education (among adults aged 21 or older), or if their mothers had less than a high 
school education (among adults aged 18 to 20). We coded them as having low numeracy 
(i.e., difficulty understanding and working with numbers) if they responded “Don’t know” or 
incorrectly to the following survey item: “In general, which of these numbers shows the 
biggest risk of getting a disease? 1 in 10; 1 in 100; or 1 in 1,000.” (Lipkus et al., 2001) 
Respondents who had never tried e-cigarettes were considered “never users”; among those 
who had ever tried e-cigarettes, we describe individuals who had used in the past 30 days as 
“current users” and those who had not used in the past 30 days as “former users.”
2.3. Statistical analyses
To check whether random assignment created demographically equivalent groups by 
experimental condition, we used chi-square tests for categorical demographic variables (sex, 
race/ethnicity, region, own or mothers’ education, e-cigarette use, cigarette smoking, and 
numeracy) and linear regression for the continuous demographic variable (age). Using 
logistic regression, we examined the effects of chemical amount scenario on harm 
perceptions and interest in dual use. The “same amount” scenario was the reference category 
in these two regressions. Next, we assessed whether perceived harm mediated the 
relationship between the chemical amount scenario (coded as 0 for “same amount” and 1 for 
the “10 times more,” “100 times more,” and “chemicals present” scenarios) and interest in 
dual use. We used a Sobel test to examine the significance of the mediation effect. To 
explore the role of numeracy in participants’ responses to the scenarios, we also conducted 
exploratory analyses using the same analytic approaches as described above but stratifying 
by numeracy. Finally, we examined whether prior use of e-cigarettes changed the 
relationship between the scenario and interest in dual use (i.e., moderation). The moderation 
analysis was a logistic regression, which included the chemical amount scenario (0 for 
“same amount” and 1 for any other scenario), past e-cigarette use (0 for “no” and 1 for 
“yes”), and their interaction. The moderation analysis was conducted using the full sample, 
not stratified by numeracy, in order to avoid having small cell sizes with less precise 
estimates. We used two-tailed statistical tests and conducted analyses in 2016 using Stata 
version 13. Regression coefficients are presented as odds ratios with 95% confidence 
intervals (CIs).
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3. Results
About half of participants had not attended college (53%) (Table 1). Their mean age was 42 
years (SD = 15). The majority of participants were white (68%) and non-Hispanic (93%). A 
moderate number were low socioeconomic status (36%) or low numeracy (38%). About 
one-third each smoked 1 pack or more of cigarettes per day (32%), smoked daily but <1 
pack of cigarettes per day (38%), or only smoked some days (31%). Most (69%) smokers 
had tried e-cigarettes, but only 32% had used them in the past 30 days. Participant 
characteristics did not differ by scenario (all p > 0.05).
3.1. Effects of chemical amount scenarios
Compared with the “same amount” scenario (in which 7% were interested in dual use), more 
smokers were interested in dual use when told that cigarettes have 10 times more chemicals 
than e-cigarettes (31%, OR = 5.62, 95% CI = 3.41–9.29), 100 times more chemicals than e-
cigarettes (32%, OR = 5.89, 95% CI = 3.57–9.74), or chemicals were present in cigarettes 
but not e-cigarettes (43%, OR = 9.41, 95% CI = 5.76–15.36) (Table 2). Chemical amount 
scenarios had a similar effect on smokers’ perceptions of whether cigarettes cause more 
health problems than e-cigarettes (see Table 2). While 41% endorsed the belief that 
cigarettes cause more health problems than e-cigarettes in the “same amount” scenario, 79% 
(OR = 5.48, 95% CI = 3.79–7.92) endorsed it in response to the “10 times more” scenario, 
80% (OR = 5.62, 95% CI = 3.87–8.16) in response to the “100 times more” scenario, and 
78% (OR = 5.16, 95% CI = 3.61–7.37) in the “chemicals present only in cigarettes” 
scenario. After stratification, the low numeracy and high numeracy groups both showed the 
same pattern of results relative to the full sample.
3.2. Mediation by perceived harm
Perceptions of harm partly explained the relationship between chemical amount scenario and 
interest in dual use of cigarettes and e-cigarettes (Fig. 1). Smokers were more likely to 
perceive that cigarettes were more harmful than e-cigarettes when told that the amount of 
chemicals in cigarettes was higher than in e-cigarettes (79% vs. 41%, OR = 5.41, 95% CI = 
4.08–7.17). Perceptions about the greater harm of cigarettes compared with e-cigarettes 
were associated with more interest in dual use (37% vs. 8%, OR = 5.19, 95% CI = 3.38–
7.97). Controlling for perceived harm reduced the association between chemical amount 
scenario and interest in dual use, and the association remained statistically significant (OR = 
4.49, 95% CI = 2.81–7.20), a pattern of findings that indicates partial mediation (Sobel z = 
6.88, p < 0.001). After stratification, the low numeracy and high numeracy groups both 
showed the same pattern of mediation as in the full sample.
3.3. Moderating effect of prior e-cigarette use on interest in dual use
Smokers who had used e-cigarettes at least once in their lifetimes responded differently to 
one of the chemical amount scenarios than those who had not (i.e., moderation by prior e-
cigarette use, interaction p < 0.05). Specifically, the difference between the “100 times 
more” and “same amount” scenarios was statistically significant among e-cigarette 
experienced smokers (36% in the “100 times more” vs. 6% in the “same amount” scenarios 
were interested in dual use, p < 0.001). It was also different among the e-cigarette naïve 
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smokers (23% in the “100 times more” vs. 10% in the “same amount” scenarios were 
interested in dual use, p < 0.05). However, the difference between scenarios was larger for e-
cigarette experienced smokers.
4. Discussion
Hearing information about the amount of chemicals in cigarettes versus e-cigarettes in a 
hypothetical scenario changed smokers’ anticipated interest in changing behavior and their 
harm perceptions. Scenarios that described cigarettes as containing more chemicals than e-
cigarettes increased their anticipated endorsement of the perception that cigarettes are more 
harmful than e-cigarettes, which in turn increased interest in initiating or escalating dual use. 
E-cigarette experienced smokers were especially likely to say that they would increase their 
dual use in one of the scenarios that described reduced chemical exposure compared with e-
cigarette naïve smokers.
Chemical amount scenarios did not appear to have a clear dose-response effect on interest in 
dual use or perceived harm. Respondents may not have distinguished much among the “10 
times more,” “100 times more,” or “chemicals present only in cigarettes” scenarios because 
individuals often have difficulty interpreting information about magnitude (Hammitt and 
Graham, 1999; Neil et al., 1994) or felt that 10 times was sufficient, or “good enough,” to be 
interested in dual use and the increases beyond that (100 times or chemicals completely 
absent in e-cigarettes) were not necessary. Alternatively, as predicted by fuzzy trace theory, 
some respondents in the “10 times more” and “100 times more” scenarios may have thought 
of this information as simply “more” rather than noticing the exact amount (Corbin et al., 
2015).
The perception that cigarettes were more harmful than e-cigarettes mediated the relationship 
between chemical amount scenario and interest in dual use. This finding demonstrates that 
consumers inherently link beliefs about lower levels of constituents with beliefs about 
reduced health harms. This could have implications for FDA’s consideration of modified 
risk tobacco products. As part of FDA’s authority over tobacco products, the agency reviews 
applications from tobacco companies that want to have their products approved as modified 
risk tobacco products (O’Connor, 2012). For a product to receive approval, companies must 
demonstrate that either (a) the product causes fewer health harms or (b) the product contains 
fewer toxic constituents but is not misinterpreted by consumers as being necessarily less 
harmful. The results of this mediation analysis suggest that an e-cigarette (or likely any other 
tobacco product) may have difficulty gaining approval as a modified risk product using the 
latter pathway given that smokers automatically assumed that lower amounts of chemicals 
meant less harm to health.
Because the experimental manipulation involved numeric comparisons, we explored whether 
participants’ numeracy affected their responses. Our analyses indicated that both low 
numeracy and high numeracy participants showed the same pattern of results as in the full 
sample. Regardless of whether they were high or low numeracy, participants were more 
likely to be interested in dual use when told that cigarettes had more chemicals than e-
cigarettes and perceived harm mediated this perception. That the results did not differ 
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between the groups adds to the potential public health concern: even individuals who have 
difficulty interpreting numbers in their everyday lives were responsive to messages about 
chemical amounts in potentially problematic ways.
Personal experience with e-cigarettes changed smokers’ responses to one of the chemical 
amount scenarios. There are multiple reasons why personal experience could change 
reactions. In past research, e-cigarette users have often reported that e-cigarettes caused less 
coughing and other unpleasant side effects than cigarettes (Pepper and Brewer, 2014). If 
smokers had this type of positive experience when they tried e-cigarettes, they might be 
particularly receptive to scenarios saying that e-cigarettes have fewer chemicals than 
cigarettes. Alternatively, smokers who were familiar with e-cigarettes may have found the 
prospect of increasing use of the product less daunting than e-cigarette naïve smokers 
thinking of initiating use. The significant difference between e-cigarette experienced and e-
cigarette naïve smokers appeared in the “100 times more” scenario. This scenario may have 
seemed the most reasonable to smokers if they saw the “10 times more” scenario as 
underestimating harm reduction and the other scenarios (“same amount” of chemicals and 
“chemicals present only in cigarettes”) as implausible. Although the research about chemical 
constituents in e-cigarette aerosol is inconsistent, some studies suggest that the magnitude of 
difference in amounts of certain chemicals between aerosol and cigarette smoke is roughly 
in the hundreds (Bhatnagar et al., 2014; Burstyn, 2014; Goniewicz et al., 2014).
4.1. Study limitations
Limitations to this experiment include possible misunderstanding of the description of e-
cigarettes despite the interviewers’ instructions to think of e-cigarettes as well as “other 
vaping products” and their mention of the terms “e-hookah” and “vape pens.” We were not 
able to show respondents images of different product types because this was a phone survey. 
Another limitation is that smokers were describing their perceptions and interest in behavior 
change in response to a hypothetical situation. Finally, although one could define “dual use” 
in other ways, we focused on smokers who said they would start or increase their use of e-
cigarettes without quitting cigarette smoking. We chose this definition because additional 
tobacco product use in the absence of quitting smoking is a health concern for the individual 
in the short-run, although the longer term population-wide effects are still unknown.
5. Conclusion
FDA is required to publicly display information about the quantities of chemicals in 
cigarettes and cigarette smoke in a way that is not misleading. This information, if paired 
with information from advertising or FDA disclosures indicating that e-cigarette aerosol 
contains lower amounts of those same chemicals, could have the unfortunate effect of 
encouraging smokers to become dual users or increase their existing dual use in lieu of 
quitting smoking under the mistaken impression that they are significantly reducing their 
health risks. Although the long-term population-wide effects of widespread dual use are 
unknown (Kalkhoran and Glantz, 2015; Levy et al., 2016), initiation or escalation of dual 
use is likely problematic for individual health in the short-run. From a regulatory standpoint, 
our findings also suggest that e-cigarettes may not be able to be approved as a modified risk 
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tobacco product on the basis of reduced chemical exposure alone because the public views 
information about lower chemical amounts as inherently related to reduced health harms. 
Future research should examine whether information about the amounts of chemicals in 
cigarettes versus e-cigarettes has a different impact on smokers’ beliefs and interest in 
changing behavior after FDA regulations (including public disclosure of cigarette smoke 
constituents, manufacturer reporting of ingredients in e-liquid, and public disclosure of 
constituents in e-cigarette aerosol) are implemented (11th Congress of the United States of 
America, 2009; U.S. Food and Drug Administration, 2016). Beyond e-cigarettes and similar 
vaping devices, researchers should examine whether any tobacco products can be considered 
modified risk tobacco products on the basis of reduced chemical exposure or whether that 
approval pathway is inherently doomed to fail because of its link with perceptions of 
reduced harm to health.
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Fig. 1. 
Anticipated perceptions of harm mediate the effect of scenario on interest in dual use. Path 
values are odds ratios. Numbers in parentheses show the association between scenario and 
interest in dual use before controlling for perceived harm. Study conducted in U.S. in 2014–
2015. *p < 0.001.
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Table 1
Participant characteristics (n = 1164).
Characteristic n %
Sex
 Female 560 48.1
 Male 604 51.9
Age: mean (SD) 42.3 (14.8)
Race
 White 787 67.6
 African American 251 21.6
 American Indian or Alaska Native 45 3.9
 Asian 13 1.1
 Other or missing 68 5.8
Hispanic/Latino 83 7.1
Education
 High school or less 612 52.6
 Some college or associate’s degree 379 32.6
 Bachelor’s degree or more 173 14.9
Low socioeconomic statusa 421 36.2
Low numeracyb 446 38.3
Region
 Midwest 257 31.4
 Northeast 108 9.3
 South 666 57.3
 West 132 11.3
Current cigarette smoking
 Smoke some days 357 30.7
 Smoke every day, <1 pack per day 438 37.6
 Smoke every day, ≥1 pack per day 369 31.7
E-cigarette use
 Never used 364 31.3
 Used but not in past 30 days 432 37.1
 Used in past 30 days 368 31.6
Note. Missing values (<0.5% per variable) recoded to mode. SD = standard deviation. Study conducted in U.S. in 2014–2015.
a
Defined as having less than a high school education or a household income below the federal poverty level.
b
Defined as an incorrect or “don’t know” response to the item, “In general, which of these numbers shows the biggest risk of getting a disease? 1 in 
10; 1 in 100; or 1 in 1000.”
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